UK firms push for faster NHS access to cutting-edge drugs
Fieldfisher’s legal experts emphasize that converting scientific advances into NHS-approved treatments involves multiple stages, including regulatory approval, health technology assessments, and funding decisions. The entire process can extend over several years, during which patients and clinicians may struggle to obtain access to transformative drugs. According to the firm’s analysis, innovative therapies must first overcome bureaucratic and financial obstacles before they can be adopted.
Patient and caregiver involvement is essential for improving treatment access. A Q&A session supported by Gilead Sciences and featuring its UK and Ireland general manager, Peter Wickersham, shows the importance of centering those affected by diseases in the development of new therapies.
Clinical trials, which provide the evidence required for approval, often face preventable delays. Dr. Richard Graham of TruTechnologies highlights recurring issues such as sample contamination, errors in patient instructions, and unanswered queries that can disrupt enrollment. He argues that these operational challenges receive less attention than the design phase of trials.
Read Also: Gilead urges community-led design for medicine access
Advancements in technology are helping to streamline healthcare innovation. Dr. Anton Yuryev, consulting director at Elsevier, describes how artificial intelligence is transforming data analysis and decision-making in drug development. Meanwhile, manufacturing innovations, such as the X-ray inspection systems discussed by Adam Green of Mettler Toledo, ensure pharmaceutical and medical device production adheres to strict quality standards.
Collaborations between pharmaceutical companies, healthcare providers, and technology firms are key to addressing these challenges. Gita Mendis, whose firm received the Excellence in Healthcare Partnerships Award for Pharmaceuticals, states that joint projects accelerate adoption by aligning incentives and expertise across industries.
In Scotland, the NHS is implementing neonatal initiatives to enhance newborn health outcomes, while a £240 million investment in digitalization aims to reduce administrative burdens related to patient records. In England, Leicester Hospital Trust has been awarded a five-year contract to deliver a new diabetes management service under the Healthy Living program.
